[A18-70] Cabozantinib (renal cell carcinoma) - Addendum to Commission A18-37
Last updated 06.12.2018
Project no.:
A18-70
Commission:
Commission awarded on 22.10.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment-naive adults with advanced renal cell carcinoma (intermediate or poor risk)
Result of dossier assessment:
Conclusion of dossier assessment A18-37 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-37 | Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-12-06 A G-BA decision was published.